OTLK
Outlook Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-0.31
P/S
40.15
EV/EBITDA
-0.60
DCF Value
$2.32
FCF Yield
-181019981.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-588.7%
Operating Margin
-28675.8%
Net Margin
-50045.1%
ROE
293.1%
ROA
-564.0%
ROIC
-983.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $-1.2M | $-23.1M | $-0.38 |
| Q4 2025 | $-91.8K | $-13.3M | $-0.52 |
| FY 2025 | $1.4M | $-62.4M | $-1.79 |
| Q3 2025 | $1.5M | $-20.2M | $-0.55 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.19
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.